MedTrace Logo

Efficacy Study of Nicorandil on Neointima

NCT02328521 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2015-01-21

No results posted yet for this study

Summary

The investigators aim to investigate the effect of oral nicorandil on neointima after coronary drug-eluting stent implantation in patients with diabetic mellitus.

Conditions

Interventions

DRUG

Nicorandil

Nicorandil is given once before PCI and given 3 times daily for 30 days after PCI.

DRUG

nicorandil placebo

Nicorandil placebo is given once before PCI and given 3 times daily for 30 days after PCI.

Sponsors & Collaborators

  • Zhang Ying Qian

    lead OTHER

Principal Investigators

  • Yundai Chen, M.D. · Chinese PLA General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2016-06-30
Completion
2016-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02328521 on ClinicalTrials.gov